Adenosine upregulates VEGF expression in cultured myocardial vascular smooth muscle cells

被引:44
作者
Gu, JW
Brady, AL
Anand, V
Moore, MC
Kelly, WC
Adair, TH
机构
[1] Univ Mississippi, Med Ctr, Dept Physiol & Biophys, Jackson, MS 39216 USA
[2] Univ Mississippi, Med Ctr, Ctr Excellence Cardiovasc Renal Res, Jackson, MS 39216 USA
来源
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY | 1999年 / 277卷 / 02期
关键词
vascular endothelial growth factor; hypoxia; normoxia; vascular smooth muscle cells; adenosine receptor; vascular maintenance factor;
D O I
10.1152/ajpheart.1999.277.2.H595
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We tested whether adenosine has differential effects on vascular endothelial growth factor (VEGF) expression under normoxic and hypoxic conditions, and whether A(1) or A(2) receptors (A(1)R; A(2)R) mediate these effects. Myocardial vascular smooth muscle cells (MVSMCs) from dog coronary artery were exposed to hypoxia (1% O-2) Or normoxia (20% O-2) in the absence and presence of adenosine agonists or antagonists for 18 h. VEGF protein levels were measured in media with ELISA. VEQF mRNA expression was determined with Northern blot analysis. Under normoxic conditions, the adenosine A(1)R agonists, N-6-cyclopentyladenosine and R(-)-N-6-(2-phenylisopropyl)adenosine did not increase VEGF protein levels at A(1)R stimulatory concentrations. However, adenosine (5 mu M) and the adenosine A(2)R agonist N-6-[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)]ethyl adenosine (DPMA; 100 nM) increased VEGF protein levels by 51 and 132% and increased VEGF mRNA expression by 44 and 90%, respectively in cultured MVSMCs under normoxic conditions. Hypoxia caused an approximately fourfold increase in VEGF protein and mRNA expression, which could not be augmented with exogenous adenosine, A(2)R agonist (DPMA), or A(1)R agonist [1,3-diethyl-8-phenylxanthine (DPX)]. The A(2)R antagonist 8-(3-chlorostyryl)-caffeine completely blocked adenosine-induced VEGF protein and mRNA expression and decreased baseline VEGF protein levels by up to similar to 60% under normoxic conditions but only by similar to 25% under hypoxic conditions. The A(1)R antagonist DPX had no effect. These results are consistent with the hypothesis that 1) adenosine increases VEGF protein and mRNA expression by way of A(2)R. 2) Adenosine plays a major role as an autocrine factor regulating VEGF expression during normoxic conditions but has a relatively minor role during hypoxic conditions. 3) Endogenous adenosine can account for the majority of basal VEGF secretion by MVSMCs under normoxic conditions and could therefore be a maintenance factor for the vasculature.
引用
收藏
页码:H595 / H602
页数:8
相关论文
共 39 条
[1]   VASCULAR DEVELOPMENT IN CHICK-EMBRYOS - A POSSIBLE ROLE FOR ADENOSINE [J].
ADAIR, TH ;
MONTANI, JP ;
STRICK, DM ;
GUYTON, AC .
AMERICAN JOURNAL OF PHYSIOLOGY, 1989, 256 (01) :H240-H246
[2]   GROWTH-REGULATION OF THE VASCULAR SYSTEM - EVIDENCE FOR A METABOLIC HYPOTHESIS [J].
ADAIR, TH ;
GAY, WJ ;
MONTANI, JP .
AMERICAN JOURNAL OF PHYSIOLOGY, 1990, 259 (03) :R393-R404
[3]  
ADAIR TH, 1991, ROLE ADENOSINE ADENI, P443
[4]   Induction and maintenance of increased VEGF protein by chronic motor nerve stimulation in skeletal muscle [J].
Annex, BH ;
Torgan, CE ;
Lin, PN ;
Taylor, DA ;
Thompson, MA ;
Peters, KG ;
Kraus, WE .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1998, 274 (03) :H860-H867
[5]   ACTIVITIES AND SOME PROPERTIES OF 5'-NUCLEOTIDASE, ADENOSINE KINASE AND ADENOSINE-DEAMINASE IN TISSUES FROM VERTEBRATES AND INVERTEBRATES IN RELATION TO CONTROL OF CONCENTRATION AND PHYSIOLOGICAL-ROLE OF ADENOSINE [J].
ARCH, JRS ;
NEWSHOLME, EA .
BIOCHEMICAL JOURNAL, 1978, 174 (03) :965-977
[6]  
BELARDINELLI L, 1992, NEWS PHYSIOL SCI, V7, P52
[7]   RELEASE OF ADENOSINE FROM ISCHEMIC BRAIN - EFFECT ON CEREBRAL VASCULAR-RESISTANCE AND INCORPORATION INTO CEREBRAL ADENINE-NUCLEOTIDES [J].
BERNE, RM ;
RUBIO, R ;
CURNISH, RR .
CIRCULATION RESEARCH, 1974, 35 (02) :262-271
[8]  
BRUNS RF, 1990, ANN NY ACAD SCI, V603, P211
[9]  
CLAFFEY KP, 1992, J BIOL CHEM, V267, P16317
[10]  
COLLIS MG, 1993, TRENDS PHARMACOL SCI, V14, P360